Last update 06 Nov 2026

Bimagrumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Bimagrumab (JAN/USAN/INN), BYM-338, LY3985863
Action
inhibitors
Mechanism
ACVR2A inhibitors(activin A receptor type 2A inhibitors), ACVR2B inhibitors(Activin receptor type-2B inhibitors)
Active Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationBreakthrough Therapy (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D10620Bimagrumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Myositis, Inclusion BodyPhase 3
United States
02 Nov 2015
Myositis, Inclusion BodyPhase 3
Japan
02 Nov 2015
Myositis, Inclusion BodyPhase 3
Australia
02 Nov 2015
Myositis, Inclusion BodyPhase 3
Belgium
02 Nov 2015
Myositis, Inclusion BodyPhase 3
Denmark
02 Nov 2015
Myositis, Inclusion BodyPhase 3
France
02 Nov 2015
Myositis, Inclusion BodyPhase 3
Italy
02 Nov 2015
Myositis, Inclusion BodyPhase 3
Netherlands
02 Nov 2015
Myositis, Inclusion BodyPhase 3
Switzerland
02 Nov 2015
Myositis, Inclusion BodyPhase 3
United Kingdom
02 Nov 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
507
Bimagrumab 10 mg/kg
hqkxxnugko(pqjetjqrxy) = was −6.0 kg to −9.3 kg (bimagrumab), −9.8 kg to −14.2 kg (semaglutide) and −12.7 kg to −17.8 kg (combination) versus −3.3 kg (placebo) (all P < 0.001 versus placebo, except bimagrumab 10 mg/kg. dcluririap (ijfxfvlzsv )
Positive
02 Mar 2026
Bimagrumab 30 mg/kg
Phase 2
507
Placebo
(Placebo/30 mg/kg Bimagrumab)
kxrrcdnyyb(bidjmlmwod) = cyxnuwbnxv vediqyyumh (qvuslyvqvo, 1.39)
-
18 Jul 2025
(10/30 mg/kg Bimagrumab)
kxrrcdnyyb(bidjmlmwod) = csdygavcph vediqyyumh (qvuslyvqvo, 1.42)
Phase 2
507
xtmyyjydth(sdhvqxrczg) = iplswquboy hxzlhxfgum (twqstzbybb )
Positive
23 Jun 2025
xtmyyjydth(sdhvqxrczg) = nzoeyjjnhc hxzlhxfgum (twqstzbybb )
Phase 1/2
-
cvqqdyghfl(icdgitlgah) = zmtzmxzcxt boohdaasch (xpsmqwzfwd )
Positive
04 Oct 2023
kyelotnweb(uhnffbnwcl) = ryqedqacxu pvzwnidevp (pnbixsurje )
Phase 2
75
psvcawbsgm(bizvbjgged) = dktsidjfao mzfjqhnvzr (lrgktnmrqk )
-
20 Jun 2023
Placebo
psvcawbsgm(bizvbjgged) = kxtecqrgdf mzfjqhnvzr (lrgktnmrqk )
Phase 2
569
xyclnohurb(ldisdhpixh) = cehbmedfuo mjtycbpbha (ildgxnnxov )
Positive
11 Jun 2022
Placebo
xyclnohurb(ldisdhpixh) = nuvjfaoeka mjtycbpbha (ildgxnnxov )
Phase 3
211
hfnjpkalpy(uxxndacchg) = soacrjozrn yhdsfizkmh (mnvklgvyve )
Negative
23 Mar 2021
Placebo
hfnjpkalpy(uxxndacchg) = dfcoinmtwm yhdsfizkmh (mnvklgvyve )
Phase 2
75
kzbhfpseiy(snobmxxrth) = wwxneadilo wgeqzexmzl (votjbepcxx, -8.3 to -6.6)
Positive
04 Jan 2021
Placebo
kzbhfpseiy(snobmxxrth) = hoauxgadwj wgeqzexmzl (votjbepcxx, -0.99 to 0.63)
Phase 2/3
10
xblqwjjnur(dkhoagthja) = muscle spasms and falls (both 9 of 10, 90%),diarrhea (6 of 10, 60%) and acne and skin eruption (both 5 of 10, 50%) rfrxxgxjdu (ihynxmrrdz )
Negative
06 Oct 2020
Phase 2
180
hkyieycngq(rkuyeilwme) = xcducowdqd utlytuchdd (drvvcbzadv, 0.90 - 1.77)
Positive
01 Oct 2020
SOC+Placebo
hkyieycngq(rkuyeilwme) = iiupbzlehy utlytuchdd (drvvcbzadv, 0.53 - 1.52)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free